

## 2<sup>nd</sup> International Conference on **Clinical Trials and Therapeutic Drug Monitoring**

August 22-24, 2016 Philadelphia, USA

### A modern *in vivo* pharmacokinetic (PK) paradigm: Combining snapshot, rapid and full PK approaches to support early drug discovery

Chun Li

Genomics Institute of the Novartis Research Foundation, USA

Successful drug discovery relies on selection of drug candidates with good *in vitro* ADME and *in vivo* pharmacokinetic properties as well as appropriate preclinical efficacy and safety profiles. However, *in vivo* animal pharmacokinetic studies are still conducted in a traditional low throughput manner, and therefore, are often the bottlenecks of discovery projects in many pharmaceutical companies. This presentation will focus on the tiered *in vivo* PK approaches, including snapshot PK, rapid PK and full PK study designs which we have implemented to support our drug discovery efforts. In all 3 approaches, compound is dosed and analyzed discretely, thereby eliminating any drug-drug interaction concerns and analysis complications typically associated with cassette dosing or cassette analysis. The rapid PK approach uses several integrated and automated processes and sample pooling strategy to improve throughput, and has become our main stream *in vivo* PK approach in the lead optimization stage. These *in vivo* PK approaches differ in throughputs, capacities, the resources required, and are designed to address the varying needs of drug discovery projects at different stages of project progression. These approaches are well integrated within discovery research, allow tremendous flexibility and are highly efficient in supporting the diverse needs and increasing demand for *in vivo* profiling. Examples of each of the tiered *in vivo* PK studies will be illustrated.

#### Biography

Chun Li has completed her MS on Analytical Chemistry from University of Waterloo, Canada. She has worked in DMPK groups within 3 different Pharmaceutical companies for over 25 years. She first joined Merck Research Laboratories in Canada in the year 1990, and then moved to Amgen in 2001 supporting both Discovery and Development DMPK. In 2008, she joined Genomics Institute of the Novartis Research Foundation (GNF) in San Diego, supporting discovery projects. She has authored or co-authored more than 35 papers in reputed journals and is a member of *American Association of Pharmaceutical Scientists (AAPS)*.

[cli4@gnf.org](mailto:cli4@gnf.org)

#### Notes: